Anti-Israel activist Mahmoud Khalil argues Oct. 7 terror attack was ‘desperate attempt' by Palestinians to ‘break the cycle'
The former Columbia University student, who was detained for over three months by the Trump administration for his prominent role in antisemitic campus protests, offered his thin rationale for the deadliest terror attack on the Jewish State in an interview with New York Times journalist Ezra Klein, who repeatedly asked Khalil to clarify his remarks.
3 Khalil blamed Israel for the Oct. 7, 2023, Hamas terror attack, arguing the Israeli government was 'absolutely ignoring Palestinians' during Abraham Accord negotiations ahead of the massacre.
Getty Images
Advertisement
'To me, it felt frightening that we had to reach this moment in the Palestinian struggle,' Khalil said, when asked about what he was thinking on the day of the attack that killed more than 1,000 people in Israel, mostly civilians.
'I remember I didn't sleep for a number of days, and Noor [Khalil's wife] was very worried about my health. It was heavy. I still remember. I was like: 'This couldn't happen,'' he added.
'The Ezra Klein Show' host followed up by asking: 'What do you mean we had to reach this moment? What moment is this?'
Advertisement
'You can see that the situation is not sustainable,' Khalil responded, referring to tensions between Israel and Gaza and the West Bank in the run-up to Oct. 7.
'You have an Israeli government that's absolutely ignoring Palestinians,' he argued. 'They are trying to make that deal with Saudi and just happy about their Abraham Accord without looking at Palestinians — as if Palestinians are not part of the equation. They circumvented the Palestinian question.'
'It was clear that it was becoming more and more violent. By Oct. 6, over 200 Palestinians were killed by Israeli forces and settlers. Over 40 of them were children. So that's what I mean by: Unfortunately, we couldn't avoid such a moment.'
Klein later asked Khalil if he felt the attack was something 'Hamas must have wanted' to drag Israel into an all-out war or rather an event 'that needed to happen to break the equilibrium.'
Advertisement
'It's more the latter — just to break the cycle, to break that Palestinians are not being heard,' Khalil argued. 'And to me, it's a desperate attempt to tell the world that Palestinians are here, that Palestinians are part of the equation.'
'That was my interpretation of why Hamas did the Oct. 7 attacks on Israel.'
3 The Trump administration claims Khalil was engaged in activities 'aligned with Hamas' at Columbia University.
James Keivom
3 Khalil has previously refused to condemn Hamas.
AFP via Getty Images
Advertisement
Khalil declined to characterize the attack as a 'mistake,' when asked by Klein, but acknowledged that 'targeting civilians is wrong.'
'Unfortunately, these horrible things happened, but we cannot ask Palestinians to be perfect victims,' the activist continued.
Khalil was arrested by federal immigration authorities on March 8 and spent 104 days at a Louisiana detention center as the Trump administration fought to deport the Syrian-born permanent resident.
The administration said Khalil, who is now suing the federal government for $20 million over his detainment, engaged in activities 'aligned to Hamas.'
Last month, in a heated CNN interview, Khalil flatly refused to condemn Hamas over the Oct. 7 attack – calling the question from host Pamela Brown 'disingenuous.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
17 minutes ago
- NBC News
Trump administration to scale back annual human rights reports
WASHINGTON — The Trump administration is scaling back the State Department 's annual Human Rights Report and placing a new focus on restrictions on freedom of expression by U.S. allies as well as adversaries. The reports, which are widely anticipated and read around the world, have been composed by U.S. diplomats under congressional mandate for almost 50 years as a measure of countries' adherence to internationally recognized human rights. The report for last year, which normally would have been released in the spring, has already been delayed by months. 'The 2024 Human Rights Report has been restructured in a way that removes redundancies, increases report readability and is more responsive to the legislative mandates that underpin the report,' a senior State Department official said Wednesday in a briefing to reporters. 'We call out certain abuses that we think deserve highlighting, but just because we focus on one instance does not mean that we are not aware of other instances of human rights abuses,' the official added, noting that all 198 countries and territories were listed in the reports. The delay follows dramatic cuts to the State Department's Bureau of Democracy, Human Rights and Labor, including the elimination of almost every office as part of the mass reorganization of the agency earlier this year. The official dismissed concerns about staffing shortages and said the draft version that had been received from the Biden administration prioritized things 'the American people rejected,' noting that 'the process of revising and ensuring that the report is readable and is factually based took several months.' The official said the report is still being finalized but would be transmitted to Congress 'in the near future.' When the 2024 report is released it will reflect the values of this administration, the official said, including concerns about a global threat to freedom of expression. 'Governments around the world continue to use censorship, arbitrary or unlawful surveillance and restrictive laws against disfavored voices, often on political and religious grounds,' the official said. The official cited Vice President JD Vance's controversial speech to the Munich Security Conference in February, during which he accused European Union leaders of suppressing free speech, particularly that of far-right groups. 'We are committed to having frank conversations with our allies, our partners and also our adversaries, to promote freedom of expression around the world,' the official said. The report will also focus on the right to life, 'the most cherished fundamental human right of all,' the official said. 'When governments are using means to hurt life, to destroy life, whether that be through war, whether that be through transnational repression, whether that be through extrajudicial killings, those are issues that we're going to raise.' The official declined to directly address whether the report would address other human rights concerns such as government corruption and restrictions on participation in the political process, the denial of freedom of movement or peaceful assembly and access to free and fair elections.
Wall Street Journal
19 minutes ago
- Wall Street Journal
Gold Steady as Traders Assess Geopolitical, Tariff Developments
2339 GMT — Gold is steady in the early Asian session as traders assess geopolitical and tariff developments. On the one hand, President Trump said there was a 'good chance' he would meet soon with Russian President Putin about the war in Ukraine, which might reduce the precious metal's safe-haven appeal. On the other hand, Trump is doubling tariffs on India to 50% with India condemning the new tariffs, which could increase U.S.-India trade tensions. 'The coming hours and days may play a key role in shaping [gold] market dynamics,' says Samer Hasn, senior market analyst at in an email. Spot gold is 0.1% higher at $3,368.47/oz. (
Wall Street Journal
22 minutes ago
- Wall Street Journal
No Alzheimer's Drug for Old Men?
Increasing evidence shows that anti-amyloid Alzheimer's treatments can slow disease progression and give patients years more of quality time with loved ones. So will the Trump Administration at long last drop the Biden rules that restrict access to these medicines? Two studies presented at the Alzheimer's Association International Conference last week show that the benefits of amyloid-clearing monoclonal antibodies by Eli Lilly and Biogen-Eisai grow over time. The drugs slowed cognitive decline in clinical trials used for Food and Drug Administration approval by some 25% to 36% over 18 months. In follow-up studies, these benefits doubled at three years for Lilly's treatment and roughly quadrupled over four years for Biogen-Eisai's. That's great news for patients.
